Alistair Milnes Sells 3,416 Shares of Bicycle Therapeutics (NASDAQ:BCYC) Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) COO Alistair Milnes sold 3,416 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $22,067.36. Following the transaction, the chief operating officer directly owned 136,717 shares of the company’s stock, valued at $883,191.82. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Alistair Milnes also recently made the following trade(s):

• On Friday, January 2nd, Alistair Milnes sold 3,244 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $6.80, for a total value of $22,059.20.

Bicycle Therapeutics Price Performance

Shares of BCYC opened at $6.87 on Thursday. Bicycle Therapeutics PLC Sponsored ADR has a 12 month low of $6.03 and a 12 month high of $15.43. The stock has a fifty day moving average price of $6.95 and a 200 day moving average price of $7.42. The company has a market cap of $476.57 million, a P/E ratio of -1.90 and a beta of 1.52.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.24. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The company had revenue of $11.73 million for the quarter, compared to analysts’ expectations of $8.25 million. As a group, research analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current year.

Bicycle Therapeutics News Roundup

Here are the key news stories impacting Bicycle Therapeutics this week:

• Neutral Sentiment: Recent quarterly results showed an EPS beat and revenue above expectations in October, which supports valuation despite continued losses; analyst coverage is mixed (some raised targets, others downgraded), leaving the consensus view around a “Hold.” MarketBeat — BCYC overview
• Negative Sentiment: CEO Kevin Lee sold a total of 21,314 shares across transactions on Jan. 2 and Jan. 5 (avg prices ≈ $6.80 and $6.46), reducing his stake by ~1.6–1.7% though he still holds roughly ~619k shares. Such sizable CEO selling can be read as a near-term negative signal for sentiment. SEC Form 4 — Kevin Lee
• Negative Sentiment: CFO Alethia Young sold 7,623 shares across Jan. 2 and Jan. 5 (avg prices ≈ $6.80 and $6.49), trimming her position by ~3.5–4.7%; insider CFO selling typically raises governance/sentiment concerns even when sizes are modest. SEC Form 4 — Alethia Young
• Negative Sentiment: COO Alistair Milnes sold ~6,660 shares across the two dates (avg prices ≈ $6.80 and $6.46), a ~2.3–2.4% reduction; multiple officers selling in the same window amplifies negative sentiment even if each trade is a small percentage of holdings. SEC Form 4 — Alistair Milnes
• Negative Sentiment: CAO Travis Alvin Thompson sold ~2,432 shares across Jan. 2 and Jan. 5 (avg prices ≈ $6.80 and $6.45), a modest trim but part of the broader insider-selling pattern. SEC Form 4 — Travis Alvin Thompson

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC lifted its position in Bicycle Therapeutics by 6.4% in the third quarter. Armistice Capital LLC now owns 2,978,000 shares of the company’s stock worth $23,050,000 after purchasing an additional 178,000 shares during the period. Long Focus Capital Management LLC raised its stake in shares of Bicycle Therapeutics by 7.7% in the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after buying an additional 101,402 shares in the last quarter. Moore Capital Management LP lifted its holdings in shares of Bicycle Therapeutics by 66.7% in the third quarter. Moore Capital Management LP now owns 125,000 shares of the company’s stock valued at $968,000 after buying an additional 50,000 shares during the period. Citadel Advisors LLC boosted its stake in Bicycle Therapeutics by 20.3% during the third quarter. Citadel Advisors LLC now owns 189,027 shares of the company’s stock valued at $1,463,000 after buying an additional 31,860 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in Bicycle Therapeutics by 21.7% during the third quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock valued at $116,000 after buying an additional 2,668 shares in the last quarter. Institutional investors own 86.15% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Citizens Jmp raised their price target on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a research note on Friday, October 31st. Truist Financial assumed coverage on Bicycle Therapeutics in a report on Monday, November 24th. They issued a “hold” rating and a $10.00 price objective for the company. Royal Bank Of Canada restated a “sector perform” rating and issued a $11.00 target price (down from $27.00) on shares of Bicycle Therapeutics in a research report on Friday, October 31st. JMP Securities set a $12.00 price target on Bicycle Therapeutics in a research report on Friday, October 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $19.73.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.